Genetic Technologies Stock Fundamentals
GTG Stock | 0.04 0.00 0.00% |
Genetic Technologies fundamentals help investors to digest information that contributes to Genetic Technologies' financial success or failures. It also enables traders to predict the movement of Genetic Stock. The fundamental analysis module provides a way to measure Genetic Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genetic Technologies stock.
At this time, Genetic Technologies' Interest Expense is comparatively stable compared to the past year. Cost Of Revenue is likely to gain to about 3.9 M in 2024, whereas Gross Profit is likely to drop slightly above 3.8 M in 2024. Genetic | Select Account or Indicator |
Genetic Technologies Company Profit Margin Analysis
Genetic Technologies' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genetic Technologies Profit Margin | (1.24) % |
Most of Genetic Technologies' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Based on the latest financial disclosure, Genetic Technologies has a Profit Margin of -1.2424%. This is much lower than that of the Life Sciences Tools & Services sector and significantly lower than that of the Health Care industry. The profit margin for all Australia stocks is notably higher than that of the company.
Genetic Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genetic Technologies's current stock value. Our valuation model uses many indicators to compare Genetic Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genetic Technologies competition to find correlations between indicators driving Genetic Technologies's intrinsic value. More Info.Genetic Technologies is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genetic Technologies' earnings, one of the primary drivers of an investment's value.Genetic Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.Genetic Technologies is currently under evaluation in profit margin category among its peers.
Genetic Fundamentals
Return On Equity | -1.85 | ||||
Return On Asset | -0.63 | ||||
Profit Margin | (1.24) % | ||||
Operating Margin | (1.13) % | ||||
Current Valuation | 5.53 M | ||||
Shares Outstanding | 145.42 M | ||||
Shares Owned By Insiders | 5.56 % | ||||
Price To Book | 3.10 X | ||||
Price To Sales | 0.59 X | ||||
Revenue | 7.66 M | ||||
Gross Profit | 6.01 M | ||||
EBITDA | (11.43 M) | ||||
Net Income | (12.02 M) | ||||
Total Debt | 875.19 K | ||||
Book Value Per Share | 0.01 X | ||||
Cash Flow From Operations | (9.68 M) | ||||
Target Price | 0.25 | ||||
Number Of Employees | 55 | ||||
Beta | 0.48 | ||||
Market Capitalization | 5.67 M | ||||
Total Asset | 6.19 M | ||||
Retained Earnings | (166.38 M) | ||||
Working Capital | (500.09 K) | ||||
Net Asset | 6.19 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 741.6 K | 778.7 K | |
Total Revenue | 7.7 M | 5.3 M | |
Cost Of Revenue | 3.8 M | 3.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.